Quantcast

Latest Lorcaserin Stories

2010-09-16 15:42:00

SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available data do not adequately demonstrate that the potential benefits of lorcaserin outweigh the potential risks, when used long-term in a population of overweight and obese individuals to allow marketing approval....

2010-09-15 07:03:00

DENVER, Sept. 15 /PRNewswire/ -- On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting. Dr. Bruner is a past president of the American Society of Bariatric Physicians (ASBP) and will speak to the committee on behalf of the Society's nearly 1,300 members throughout the U.S. ASBP's physicians know from long experience that...

2010-09-13 07:00:00

SAN DIEGO, Sept. 13, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will host a conference call and webcast on Friday, September 17, 2010, at 7:00 a.m. Eastern Time (4:00 a.m. Pacific Time) following the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting. The committee is scheduled to meet on September 16, 2010, to review the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena...

2010-08-06 08:20:00

SAN DIEGO and WOODCLIFF LAKE, N.J., Aug. 6, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed for weight management, is intended for...

2010-08-06 02:30:00

SAN DIEGO, Aug. 6, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it has agreed to sell a total of 8,955,224 shares of its common stock, at a price of $6.70 per share, in a registered direct public offering to entities affiliated with Deerfield Management, a healthcare investment organization. Arena expects to receive gross proceeds, before expenses, of approximately $60 million. The closing of the offering is expected to take place on or...

2010-08-03 15:03:00

SAN DIEGO, Aug. 3, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA. "We have recently achieved a number of important milestones, including the establishment of an agreement with Eisai for the...

2010-08-03 12:00:00

SAN DIEGO, Aug. 3, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that the company is scheduled to present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010, at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time) at the Sheraton New York Hotel & Towers in New York City. Jack Lief, Arena's President and Chief Executive Officer, is scheduled to provide a corporate overview. A live audio webcast of...

2010-07-27 07:00:00

SAN DIEGO, July 27, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report second quarter 2010 financial results after the NASDAQ Global Market closes on Tuesday, August 3, 2010. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial...

2010-07-14 16:00:00

SAN DIEGO and WOODCLIFF LAKE, N.J., July 14 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. today announced that results from the two-year BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial will be published in the July 15, 2010, issue of the New England Journal of Medicine. The data presented in the article show that lorcaserin used in conjunction with behavioral modification caused significantly greater weight...

17725ca7200c4b9d003891545b26401b
2010-07-13 06:20:49

Doctors are getting their first glimpse at a new weight loss drug this week. The doctors hope that the drug, which is one of three new weight loss drugs coming out, can succeed where many others have failed by delivering significant weight loss without risky side effects. With U.S. Obesity rates closing in at 35 percent of the adult population, expectations are high for the first new prescription drug therapies that have been emerging for over a decade.  Even a modestly effective drug...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related